Brain dopamine–clock interactions regulate cardiometabolic physiology: mechanisms of the observed cardioprotective effects of circadian-timed bromocriptine-QR …
AH Cincotta - International Journal of Molecular Sciences, 2023 - mdpi.com
Despite enormous global efforts within clinical research and medical practice to reduce
cardiovascular disease (s)(CVD), it still remains the leading cause of death worldwide. While …
cardiovascular disease (s)(CVD), it still remains the leading cause of death worldwide. While …
Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary
P Raskin, AH Cincotta - Expert review of endocrinology & …, 2016 - Taylor & Francis
An extended series of studies indicate that endogenous phase shifts in circadian neuronal
input signaling to the biological clock system centered within the hypothalamic …
input signaling to the biological clock system centered within the hypothalamic …
Novel trajectories of bromocriptine antidiabetic action: Leptin-IL-6/JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/adiponectin, Nrf2/PARP-1, and GLP-1
E Reda, S Hassaneen, HS El-Abhar - Frontiers in Pharmacology, 2018 - frontiersin.org
Bromocriptine (BC), a sympatholytic dopaminergic D2 receptor agonist, has been
comprehensively used in clinic to treat Parkinson's disease (PD) and prolactinomas …
comprehensively used in clinic to treat Parkinson's disease (PD) and prolactinomas …
Timed bromocriptine‐QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well‐controlled type 2 diabetes mellitus
B Chamarthi, JM Gaziano, L Blonde… - Journal of Diabetes …, 2015 - Wiley Online Library
Background. Type 2 diabetes (T2DM) patients, including those in good glycemic control,
have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control …
have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control …
Circadian‐timed dopamine agonist treatment reverses high‐fat diet‐induced diabetogenic shift in ventromedial hypothalamic glucose sensing
CR Stoelzel, Y Zhang… - Endocrinology, Diabetes & …, 2020 - Wiley Online Library
Introduction Within the ventromedial hypothalamus (VMH), glucose inhibitory (GI) neurons
sense hypoglycaemia while glucose excitatory (GE) neurons sense hyperglycaemia to …
sense hypoglycaemia while glucose excitatory (GE) neurons sense hyperglycaemia to …
Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor
SN Framnes-DeBoer, E Bakke… - American Journal …, 2020 - journals.physiology.org
Bromocriptine, a dopamine D2 receptor agonist originally used for the treatment of
hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose …
hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose …
Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin
Objectives: Type 2 diabetes mellitus (T2DM) is associated with a substantially increased risk
of cardiovascular disease (CVD). Bromocriptine-QR (B-QR), a quick release sympatholytic …
of cardiovascular disease (CVD). Bromocriptine-QR (B-QR), a quick release sympatholytic …
Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin
B Chamarthi, AH Cincotta - Postgraduate Medicine, 2017 - Taylor & Francis
Objective: The concurrent use of an insulin sensitizer in type 2 diabetes mellitus (T2DM)
patients with inadequate glycemic control on basal-bolus insulin may help improve glycemic …
patients with inadequate glycemic control on basal-bolus insulin may help improve glycemic …
Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus
SS Schwartz, F Zangeneh - Postgraduate medicine, 2016 - Taylor & Francis
Objectives: To provide an evidence-based practice overview on the clinical use of
bromocriptine-quick release (QR) across the natural history of type 2 diabetes mellitus …
bromocriptine-quick release (QR) across the natural history of type 2 diabetes mellitus …
The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations
AJ Garber, L Blonde, ZT Bloomgarden, Y Handelsman… - Endocrine Practice, 2013 - Elsevier
Objective To review available data on the efficacy and safety of bromocriptine-QR (BQR)
and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods …
and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods …